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The purpose of this study was to examine the effect on survival of delaying the start of adjuvant chemotherapy for early breast cancer
for up to 3 months after surgery. In the nation-wide clinical trials of the Danish Breast Cancer Cooperative Group, 7501 breast cancer
patients received chemotherapy within 3 months of surgery between 1977 and 1999: 352 with classical cyclofosfamide, metotrexate
and 5-fluorouracil (CMF); 6065 with CMF i.v. and 1084 with cyclofosfamide, epirubicin and 5-fluorouracil. For the analysis, the time
between surgery and the start of chemotherapy was divided into four strata (1–3, 4, 5 and 6–13 weeks). The results show that
within the three groups of chemotherapy, there was an even distribution of known prognostic factors across the four strata of
initiation of chemotherapy. There was no pattern indicating a benefit from early start of chemotherapy. No significant interactions
were found for subgroups of patients with a poorer prognosis (many involved lymph nodes, high-grade malignancies or hormone
receptor negative disease). In conclusion, we have found no evidence for a survival benefit due to early initiation of adjuvant
chemotherapy within the first 2–3 months after surgery.
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It is well established that adjuvant chemotherapy reduces mortality
after early breast cancer (Early Breast Cancer Trialists’ Collabora-
tive Group, 1998). The consensus panel of the St. Gallen conference
has published guidelines as to which groups of patients should be
offered chemotherapy and which drugs to use, but there are no
recommendations on the optimal time to start chemotherapy after
surgery for breast cancer (Kaufmann et al, 2003).
Animal models have shown circulating growth factors and
accelerated growth of metastases after removal of the primary
tumour (Fisher et al, 1989). So, from a biological point of view,
early initiation would seem preferable. Perioperative chemo-
therapy has demonstrated some value in comparison with no
chemotherapy (Nissen-Meyer et al, 1986), but this advantage
seems to disappear when patients receive regular adjuvant
chemotherapy afterwards (van der Hage et al, 2001).
Six studies have assessed the influence on survival of delaying
chemotherapy. Two small studies from the 1980s reported an
improved disease-free survival (DFS) for patients starting chemo-
therapy within 4 and 5 weeks compared with the patients treated
later (Brooks et al, 1983; Pronzato et al, 1989). This finding was
supported in a more recent Turkish study (Altundag et al, 2000).
In a study from the MD Anderson Centre delays of 9, 10–13, 14–
17 and 18þ weeks did not affect DFS (Buzdar et al, 1982). In a
larger study of premenopausal women treated with cyclofosfamide,
metotrexate and 5-fluorouracil (CMF) a DFS advantage was
demonstrated only for a smaller group of patients (oestrogen
receptor absent tumours) treated within 3 weeks after definitive
surgery compared with the patients treated later (Colleoni et al,
2000). This finding could not be reproduced in a recent study from
the Royal Marsden (Shannon et al, 2003).
As the number of patients requiring adjuvant chemotherapy is
steadily increasing, often without a parallel increase in resources
allocated to delivering chemotherapy, many oncology departments
have to create waiting lists for starting chemotherapy. Such waiting
lists cause anxiety among patients and health authorities. Since it
will not be ethically acceptable to perform a trial of early vs late
start of chemotherapy, data from other types of studies are needed
to provide evidence on the effect of delays in chemotherapy on
survival. Such data are available from the nation-wide clinical trial
programme of the Danish Breast Cancer Cooperative Group
(DBCG), which has conducted randomised clinical trials of early
breast cancer since 1977.
PATIENTS AND METHODS
Study population
Between January 1977 and December 1999, we identified from the
database of the DBCG 7690 patients with early breast cancer who
received adjuvant chemotherapy. Of these, 159 (2%) patients were
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sexcluded because the initiation of chemotherapy exceeded 89 days
after surgery and 30 because of missing data on tumour size,
leaving 7501 patients available for analysis.
Study design
The clinical trial programme of DBCG and the trials DBCG-77B,
DBCG-82B and DBCG-82C have been described elsewhere
(Andersen and Mouridsen, 1988). In the 1989 protocols, eligibility
criteria for chemotherapy included node positive disease, tumours
measuring more than 50mm or malignancy grade II or III.
Receptor positive, premenopausal patients were randomised to
CMF i.v. vs castration, whereas patients with receptor-negative
tumours or with unknown receptor status were randomised
to CMF i.v.7pamidronate vs cyclofosfamide, epirubicin and
5-fluorouracil (CEF)7pamidronate. In 1998, the eligibility criteria
were changed to include patients with tumours measuring more
than 20mm, and/or node positive, and/or grade II or III and/or
receptor negative. In the protocols starting in 1999, pre- and
perimenopausal patients were treated with CEF and if receptor
positive, with tamoxifen afterwards. Postmenopausal receptor-
negative patients were treated with CMF i.v. The chemotherapy
regimens were classical CMF (C¼100mgm
 2 po days 1–14,
M¼40mgm
 2 i.v. days 1 and 8 and F¼600mgm
 2 i.v. days 1 and
8 every 4 weeks, 12 times), CMF i.v. (C¼600mgm
 2 i.v.,
M¼40mgm
 2 i.v. and F¼600mgm
 2 i.v. every 3 weeks, 9
times) and CEF (C¼600mgm
 2 i.v., E¼60mgm
 2 i.v. and
F¼600mgm
 2 i.v. every 3 weeks, 9 times).
Data on prognostic factors and treatment were collected
prospectively including age, tumour size, histological type, tumour
grade, hormone receptor status, number of involved lymph nodes,
adjuvant irradiation to chest wall and lymph nodes, adjuvant
tamoxifen, and type of chemotherapy. Tumour grade was assessed
according to the modified method of Elston and Ellis (1991).
Hormone receptor status was determined by biochemistry and
from 1990 onwards by immunohistochemistry. Tumours were
classified as receptor positive by 10% or more positivity for either
oestrogen or progesterone receptor or both.
The date of definitive surgery was defined as the date of the most
extensive procedure ordinarily including axillary lymph node
dissection, and could thus be preceded by a biopsy. Delays of
chemotherapy were defined as time from definitive surgery to start
of chemotherapy and categorised into the following strata: –21
days, 22–28 days, 29–35 days and 36–89 days. These strata were
chosen to divide the population into four equally sized groups with
one group matching the studies of Colleoni and Shannon (1–21
days).
The patients were followed by reports from the clinical
departments to the DBCG at least once per year based on the
civil personal registration number (a unique number assigned to
all Danish residents that encodes gender and date of birth). This
allows follow-up by record linkage to the Central Population
Register, which keeps updated information on vital status (dates of
death or emigration), and address (date of migration from the
county) of all residents in Denmark. Follow-up to death is thus
complete. Overall survival (OS) was defined as time from date of
definitive surgery to date of death or last follow-up, which was
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Figure 1 Interval from definitive surgery to start of chemotherapy in
7501 Danish patients.
Table 1 Distribution of prognostic factors in four groups of delayed
chemotherapy for patients treated with classical CMF, (percentages in
brackets)
Patients characteristics
Start of chemotherapy in days
Characteristic P-values o21 22–28 29–35 36–89
Total no. 58 (17) 92 (27) 75 (23) 127 (32)
Age (years) 0.1905
o46 33 (17) 50 (27) 44 (23) 61 (32)
46–55 25 (16) 37 (24) 31 (20) 60 (39)
455 0 (0) 5 (45) 0 (0) 6 (55)
Tumour size (mm) 0.4404
0–20 15 (14) 29 (26) 27 (24) 40 (36)
21–50 31 (18) 39 (23) 34 (20) 65 (38)
450 12 (18) 24 (35) 12 (18) 20 (29)
Unknown 0 0 2 (50) 2 (50)
No. of nodes 0.2252
0 8 (15) 16 (29) 5 (9) 26 (47)
1–3 27 (14) 49 (26) 46 (24) 70 (36)
4–6 16 (23) 16 (23) 15 (22) 22 (32)
46 7 (19) 11 (31) 9 (25) 9 (25)
Histological type 0.2185
Ductal 54 (17) 80 (27) 61 (20) 106 (35)
Nonductal 4 (8) 11 (22) 14 (29) 20 (41)
Unknown 0 1 (50) 0 1 (50)
Malignancy, grade 0.4533
I 11 (19) 13 (23) 9 (16) 24 (42)
II 35 (19) 46 (25) 40 (22) 63 (34)
III 8 (14) 20 (34) 11 (19) 19 (33)
Nonductal 4 (8) 11 (22) 14 (29) 20 (41)
Unknown 0 2 (50) 1 (25) 1 (25)
Receptor status 0.8585
Negative 5 (17) 9 (31) 7 (24) 8 (28)
Positive 18 (18) 26 (27) 19 (20) 34 (35)
Unknown 35 (15) 57 (25) 49 (22) 85 (38)
Radiotherapy
No 0 (0) 0 (0) 0 (0) 0 (0)
Yes 58 (16) 92 (26) 75 (21) 127 (36)
The P-values for the w
2-tests are calculated in the contingency tables without the
unknown values.
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s1 February 2003. Overall survival is reported as the best surrogate
to ‘cure’.
Statistical analysis
Baseline differences in prognostic factors between different
treatment delay groups were performed by the w
2 test. Survival
curves were calculated using the Kaplan–Meier method and
differences assessed by the log-rank statistic. The three different
chemotherapy groups were analysed separately. The Cox propor-
tional hazards model was used to test for the independent effect of
timing of chemotherapy after adjusting for known prognostic
factors and hazard ratios estimated with 95% confidence limits.
Tests were performed to study possible interaction between delay
of chemotherapy and lymph node involvement, tumour grade and
hormone receptor status.
The variables in the Cox models were as follows: start of
chemotherapy 1–21,22–28, 29–35 and 36–89 days; age 45, 46–55
Table 2 Distribution of prognostic factors in four groups of delayed
chemotherapy for patients treated with CMF, (percentages in brackets)
Patients characteristics
Start of chemotherapy in days
Characteristic P-values o21 22–28 29–35 36–89
Total no. 0.0435 1509 (25) 1581 (26) 1423 (23) 1552 (26)
Age (years)
o46 629 (26) 641 (26) 588 (24) 574 (24)
46–55 613 (25) 617 (25) 569 (23) 648 (27)
455 267 (23) 323 (27) 266 (22) 330 (28)
Tumour size (mm) 0.1083
0–20 646 (24) 712 (26) 622 (23) 708 (26)
21–50 694 (26) 699 (26) 662 (24) 652 (24)
450 156 (26) 155 (26) 122 (20) 170 (28)
Unknown 13 (19) 15 (22) 17 (25) 22 (33)
No. of nodes o0.0001
0 187 (16) 264 (23) 295 (26) 388 (34)
1–3 849 (27) 865 (28) 709 (23) 722 (23)
4–6 239 (26) 263 (28) 212 (23) 221 (24)
46 234 (28) 189 (22) 205 (24) 221 (26)
Unknown 0 0 2 (100) 0
Histological type 0.3105
Ductal 1301 (25) 1369 (26) 1238 (23) 1370 (26)
Nonductal 198 (27) 201 (27) 178 (24) 171 (23)
Unknown 10 (26) 11 (28) 7 (18) 11 (28)
Malignancy, grade 0.0651
I 254 (26) 270 (28) 193 (20) 247 (26)
II 654 (25) 660 (25) 634 (24) 661 (25)
III 360 (23) 415 (26) 384 (24) 426 (27)
Nonductal 198 (27) 201 (27) 178 (24) 171 (23)
Unknown 43 (27) 35 (22) 34 (21) 47 (30)
Receptor status o0.0001
Negative 303 (16) 446 (24) 503 (27) 602 (32)
Positive 719 (28) 663 (26) 595 (23) 620 (24)
Unknown 487 (30) 472 (29) 325 (20) 330 (20)
Radiotherapy 0.9174
No 860 (25) 912 (26) 814 (24) 876 (25)
Yes 649 (25) 669 (26) 609 (23) 676 (26)
The P-values for the w
2-tests are calculated in the contingency tables without the
unknown values.
Table 3 Distribution of prognostic factors in four groups of delayed
chemotherapy for patients treated with CEF, (percentages in brackets)
Patients characteristics
Start of chemotherapy in days
Characteristic P-values o21 22–28 29–35 36–89
Total no. 188 (17) 305 (28) 263 (24) 328 (30)
Age (years) 0.2714
o46 90 (18) 140 (28) 129 (26) 146 (29)
46–55 85 (19) 125 (28) 104 (23) 135 (30)
455 13 (10) 40 (31) 30 (23) 47 (36)
Tumour size (mm) 0.4970
0–20 78 (16) 148 (30) 118 (24) 156 (31)
21–50 92 (18) 137 (27) 129 (25) 149 (29)
450 17 (25) 18 (26) 13 (19) 21 (30)
Unknown 1 (13) 2 (25) 3 (38) 2 (25)
No. of nodes 0.2176
0 70 (16) 123 (28) 98 (22) 153 (34)
1–3 65 (19) 92 (27) 83 (24) 105 (30)
4–6 23 (18) 40 (31) 34 (26) 34 (26)
46 30 (18) 50 (30) 48 (29) 36 (22)
Histological type 0.0009
Ductal 164 (17) 282 (29) 250 (25) 287 (29)
Nonductal 24 (25) 22 (22) 11 (11) 41 (42)
Unknown 0 1 (33) 2 (67) 0
Malignancy, grade 0.0072
I 15 (17) 22 (25) 21 (24) 29 (33)
II 68 (15) 143 (31) 112 (24) 143 (31)
III 79 (19) 115 (28) 111 (27) 110 (27)
Nonductal 24 (25) 22 (22) 11 (11) 41 (42)
Unknown 1 (11) 3 (17) 8 (44) 5 (28)
Receptor status 0.1634
Negative 54 (14) 101 (27) 92 (24) 133 (35)
Positive 109 (17) 177 (29) 152 (25) 177 (29)
Unknown 25 (28) 27 (30) 19 (21) 18 (20)
Radiotherapy 0.4338
No 74 (15) 138 (29) 119 (25) 153 (32)
Yes 114 (19) 167 (28) 144 (24) 175 (29)
The P-values for the w
2-tests are calculated in the contingency tables without the
unknown values.
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Figure 2 Overall survival among 352 Danish patients with early breast
cancer treated with classical CMF according to interval from definitive
surgery to start of adjuvant chemotherapy.
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sand 56–69 years; tumour size: 0–20, 21–50 and 51þ mm; tumour
type: invasive ductal carcinoma and others; malignancy grade:I ,I I
and III; hormone receptor: positive and negative; involved axillary
lymph nodes:0 ,1 – 3 ,4 – 6a n d7þ; and adjuvant irradiation: 7.
RESULTS
Patient characteristics
A total of 7501 patients received adjuvant chemotherapy for early
breast cancer within 89 days of surgery. Of these, 352 patients
received classical CMF, 6065 CMF i.v. and 1084 CEF with median
delays of 31, 28 and 30 days, respectively. The interval from
definitive surgery to start of chemotherapy is shown in Figure 1.
Approximately 25% of the patients were treated within the first 3
weeks, another 50% between week 4 and 5, respectively, whereas
the remaining 25% started chemotherapy from weeks 6 to 13.
According to this distribution and to match previous studies the
analyses were performed in four groups of patients treated on
weeks 1–3, 4, 5 and 6–13.
Tables 1–3 show that there was an even distribution of known
prognostic factors such as age, tumour size, malignancy grade,
hormone receptor status and positive lymph nodes across the four
strata of initiation of chemotherapy within the three groups of
chemotherapy, with the exception of patients treated early with
CMF i.v. being more likely to be node positive and more likely to
be receptor positive than those treated later (Table 2).
Overall survival
Kaplan–Meier plots of OS are shown in Figures 2–4 for classical
CMF, CMF i.v., and CEF, respectively. No particular or consistent
patterns were observed according to when after surgery the
adjuvant chemotherapy started, the P-values ranging from 0.2 to
0.7. This lack of an association between start of chemotherapy and
OS was confirmed in multivariate analyses taking known prog-
nostic factors into account. Table 4 indicates a nonsignificantly
increased hazard ratio for delaying start of chemotherapy for more
than 4 weeks, but this estimate was based on only 352 patients
receiving classical CMF. Among the 6065 patients receiving CMF
i.v. (Table 5) and the 1084 patients receiving CEF (Table 6) the
hazard ratios were close to unity and the associations not
significant. Tests were performed for interactions between the
prognostic factors shown in Tables 4–6 and strata of initiation of
chemotherapy and these did not reveal any significant interactions
(data not shown).
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Figure 3 Overall survival among 6065 Danish patients with early breast
cancer treated with CMF i.v. according to interval from definitive surgery to
start of adjuvant chemotherapy.
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Figure 4 Overall survival among 1084 Danish patients with early breast
cancer treated with CEF according to interval from definitive surgery to
start of adjuvant chemotherapy.
Table 4 Hazard ratios and lower and upper confidence limits (lcl–ucl)
from multivariate analysis: overall survival according to prognostic factors
and delay of chemotherapy among 352 Danish breast cancer patients
treated with adjuvant classical CMF
Characteristics P-values Hazard ratio (lcl–ucl)
Start of chemotherapy P¼0.2658
1–3 weeks 1
4 weeks 0.929 (0.441–1.957)
5 weeks 1.549 (0.761–3.149)
6–13 weeks 1.588 (0.856–2.948)
Age (years) P¼0.9892
–45 1
46–55 0.962 (0.568–1.627)
56–69 0.997 (0.285–3.480)
Tumour size (mm) P¼0.0203
–20 1
21–50 1.843 (0.974–3.486)
51– 2.848 (1.365–5.945)
No. of nodes involved P¼0.2545
01
1–3 1.783 (0.894–3.553)
4–6 1.615 (0.725–3.596)
7– 2.318 (0.978–5.498)
Histological type P¼0.9607
Nonductal 1
Ductal 1.027 (0.355–2.975)
Malignancy grade P¼0.0553
I1
II 2.255 (1.007–5.052)
III 1.293 (0.457–3.656)
Receptor status P¼0.0199
Negative 1
Positive 0.257 (0.083–0.792)
Timing of adjuvant chemotherapy
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sThe OS analyses have also been made according to total delay
of chemotherapy (time from cytological/histological diagnosis
to start of chemotherapy). However, the substitution of delay of
treatment from definitive surgery by this total delay made
practically no difference (data not shown). The analyses have also
been performed for DFS. As the DFS curves expressed the same
pattern as the OS curves, we have only reported the OS.
The proportion of patients receiving adjuvant tamoxifen was
decreasing in relation to delay of chemotherapy, from 21% in the
group treated within 21 days in comparison to 11% in the group
treated after day 35. On the other hand, adjuvant tamoxifen did not
seem to interact with chemotherapy delay and survival (data not
shown).
In the three study groups 1020 patients were identified with
oestrogen receptor absent tumours. For the major subgroup
treated with CEF (n¼690) delay of chemotherapy seemed of no
importance (P¼0.91).
DISCUSSION
The present study shows that 98% of Danish breast cancer patients
started adjuvant chemotherapy within 3 months of definitive
surgery. Within these 3 months, we found no relation between
start of chemotherapy and OS, meaning that the prognosis was
similar for patients starting chemotherapy within 3 weeks after
surgery to those starting chemotherapy up to 13 weeks after
surgery. This is in agreement with results of other studies (Buzdar
et al, 1982; Colleoni et al, 2000; Shannon et al, 2003). There does,
however, seem to be an upper limit as to for how long time-
adjuvant chemotherapy can be postponed after surgery, results
from Turkey pointing towards approximately 5 months (Altundag
et al, 2000). If chemotherapy is delayed for more than 5 months,
then the concept of being adjuvant no longer holds.
The idea that an early initiation of adjuvant chemotherapy could
be beneficial originates from animal models demonstrating
circulating growth factors and accelerated growth of metastases
after removal of the primary tumour (Fisher et al, 1983), and that a
single dose of chemotherapy given perioperatively to mice or as an
infusion within 3 days of surgery seemed more efficient than
treatment given later (7 days) (van der Hage et al, 2001). This has
also been shown in humans (Nissen-Meyer et al, 1986). In a meta-
analysis, Clahsen et al (1997) found no OS advantage, whereas DFS
was longer for perioperative chemotherapy than for no periopera-
tive chemotherapy. However, this advantage was primarily found
in the node negative patients who were less likely to receive further
chemotherapy. When perioperative chemotherapy was combined
with postoperative, adjuvant chemotherapy, perioperative chemo-
therapy did not improve OS (Clahsen et al, 1997).
Table 5 Hazard ratios and lower and upper confidence limits (lcl–ucl)
from multivariate analysis: overall survival according to prognostic factors
and delay of chemotherapy among 6065 Danish breast cancer patients
treated with adjuvant CMF i.v.
Characteristics P-values Hazard ratio (lcl–ucl)
Start of chemotherapy P¼0.1436
1–3 weeks 1
4 weeks 1.021 (0.903–1.155)
5 weeks 0.890 (0.782–1.012)
6–13 weeks 1.002 (0.884–1.136)
Age (years) Po0.0001
–45 1
46–55 0.903 (0.813–1.003)
56–69 1.346 (1.187–1.527)
Tumour size (mm) Po0.0001
–20 1
21–50 1.480 (1.339–1.635)
51– 2.002 (1.726–2.321)
No. of nodes involved Po0.0001
01
1–3 2.248 (1.908–2.647)
4–6 3.678 (3.072–4.404)
7– 5.621 (4.713–6.704)
Histological type P¼0.2438
Nonductal 1
Ductal 0.896 (0.746–1.077)
Malignancy grade Po0.0001
I1
II 1.537 (1.329–1.779)
III 1.775 (1.515–2.080)
Receptor status Po0.0001
Negative 1
Positive 0.764 (0.691–0.844)
Adjuvant irradiation Po0.0001
  1
+ 0.745 (0.675–0.822)
Table 6 Hazard ratios and lower and upper confidence limits (lcl–ucl)
from multivariate analysis: overall survival according to prognostic factors
and delay of chemotherapy among 1084 Danish breast cancer patients
treated with adjuvant CEF
Characteristics P-values Hazard ratio (lcl–ucl)
Start of chemotherapy P¼0.6205
1–3 weeks 1
4 weeks 1.218 (0.800–1.854)
5 weeks 1.045 (0.716–1.525)
6–13 weeks 1.238 (0.861–1.782)
Age (years) P¼0.1709
–45 1
46–55 0.790 (0.562–1.111)
56–69 1.090 (0.710–1.673)
Tumour size P¼0.1579
–20 1
21–50 1.305 (0.956–1.781)
51– 1.481 (0.909–2.414)
No. of nodes involved Po0.0001
01
1–3 3.780 (2.264–6.310)
4–6 6.786 (3.928–11.723)
7– 13.297 (7.867–22.474)
Histological type P¼0.2985
Nonductal 1
Ductal 0.676 (0.323–1.414)
Malignancy grade P¼0.0583
I1
II 2.064 (1.119–3.808)
III 2.080 (1.116–3.874)
Receptor status Po0.0001
Negative 1
Positive 0.106 (0.042–0.268)
Adjuvant irradiation P¼0.1112
  1
+ 0.762 (0.545–1.065)
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tive or neoadjuvant treatment has also been explored. The NSABP-
B18 trial demonstrated no difference in DFS in women treated with
chemotherapy before surgery compared to women treated with the
same chemotherapy after surgery, also indicating no benefit from
early initiation of chemotherapy (Wolmark et al, 2001).
Two small studies have reported improved survival when
chemotherapy was given early. For a subgroup of 169 patients
treated with adjuvant AC, DFS was higher among patients with
1–3 involved lymph nodes treated within 4 weeks than among
patients treated later, but the trend was in the opposite direction
for patients with more than four involved lymph nodes (Brooks
et al, 1983). Among 229 patients receiving adjuvant CMF i.v., OS
was significantly better for the one-half of patients treated within 5
weeks in comparison with the patients treated later (Pronzato et al,
1989). Colleoni et al (2000) identified a subgroup of patients with
oestrogen receptor absent tumours who had a remarkable benefit
of being treated early, with 10-year DFS of 60 vs 34% for early vs
late treatment, respectively. We duplicated this subgroup analysis
in our material, but found no difference in OS.
The strength of the present study is that the analysis is based on
a large number of patients, in particular, the group of patients
treated with CMF i.v., thereby providing sufficient statistical power
to detect even small differences in survival. Furthermore, the study
is based on the entire Danish population for which the DBCG has
issued national guidelines to ensure uniform procedures for
surgery, pathology, chemotherapy, radiotherapy and follow-up. By
virtue of civil personal registration numbers, there was a complete
follow-up of all patients in the study.
The main limitation of this study is that it is not randomised.
The initiation of chemotherapy may have been influenced by the
physicians allocating the patients to ‘early’ treatment if they had a
poor prognosis and the physicians did not want to delay the start
of chemotherapy. In our study, patients with no involved lymph
nodes were more likely to be treated late with CMF i.v. (Table 2),
but on the other hand the patients treated late were more likely to
be receptor negative. For the CEF-treated group the trend is similar
but much less pronounced.
CONCLUSION
In conclusion, this large population-based study did not demon-
strate any benefit in OS from an early start of adjuvant
chemotherapy among Danish breast cancer patients treated within
3 months of definitive surgery, or for any subgroups with
potentially fast growing tumours according to increasing number
of involved axillary lymph nodes, increasing malignancy grade or
negative hormone receptor status. This finding is reassuring for
patients who have to delay their start of chemotherapy for health
reasons, for example, postoperative complications such as infec-
tions, or for other reasons.
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